TOKYO, December 26, 2024 -- ( BUSINESS WIRE )--Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; "Axcelead DDP") announced today that it has entered into a drug discovery service ...

A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer's disease and other neudegenerative conditions. | Drug Discovery And Development ...

TONI: I turned 65 in June, two years ago and did not enroll in Medicare because I do not have any health issues. A friend ...